Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene

Severe, life-threatening adverse reactions to capecitabine sometimes occur in the treatment of solid tumors. Screening for dihydropyrimidine dehydrogenase (DPYD) deficiency is encouraged before start of treatment, but the genetic variants that are commonly analyzed often fail to explain toxicities s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Manag Res
Autori principali: García-González, Xandra, López-Tarruella, Sara, García, María Isabel, González-Haba, Eva, Blanco, Carolina, Salvador-Martin, Sara, Jerez, Yolanda, Thomas, Fabienne, Jarama, María, Sáez, María Sanjurjo, Martín, Miguel, López-Fernández, Luis Andrés
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2018
Soggetti:
Case Report
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190816/
https://ncbi.nlm.nih.gov/pubmed/30349384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S174470
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi